Welcome to our dedicated page for Mink Therapeutics news (Ticker: INKT), a resource for investors and traders seeking the latest updates and insights on Mink Therapeutics stock.
MiNK Therapeutics, Inc. (NASDAQ: INKT) is a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (iNKT) cell therapies and precision immune technologies. The news flow around MiNK centers on its progress in oncology, graft-versus-host disease (GvHD), transplantation, and severe pulmonary inflammatory disease, reflecting the company’s focus on immune reconstitution and immune modulation.
News updates commonly highlight clinical trial milestones for its lead iNKT therapy agenT-797, including Phase 1 and Phase 2 studies in checkpoint-refractory solid tumors, GvHD prevention in allogeneic stem cell transplantation, and critical pulmonary immune failure. MiNK also reports on preclinical and translational data for next-generation programs such as MiNK-215, an IL-15–enhanced, FAP-targeting CAR-iNKT therapy designed to remodel the tumor stroma and enhance anti-tumor immunity.
Investors following INKT news can expect coverage of peer-reviewed publications, late-breaking presentations at scientific meetings, grant awards from agencies such as NIH and the Department of Defense, and philanthropic funding supporting GvHD and transplant-related studies. Corporate news items also include quarterly financial results, at-the-market equity program updates, and leadership and board appointments that the company associates with advancing its iNKT platform toward pivotal development.
This news page aggregates MiNK Therapeutics’ press releases and related market-moving announcements in one place, making it easier to track clinical data readouts, regulatory and funding developments, and strategic initiatives involving its allogeneic iNKT cell therapy pipeline.
MiNK Therapeutics (NASDAQ: INKT) and University of Wisconsin–Madison will initiate an investigator‑sponsored Phase 1 trial of allo‑iNKT cell therapy agenT‑797 to evaluate safety, tolerability, and preliminary efficacy for preventing graft‑versus‑host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation for high‑risk leukemias and other blood cancers.
The program is supported by two non‑dilutive awards: an NIAID STTR grant for preclinical development and a Mary Gooze Clinical Trial Award to fund enrollment, immune monitoring, and operations. AgenT‑797 is described as an off‑the‑shelf, HLA‑independent, lymphodepletion‑free donor‑derived iNKT therapy with prior favorable safety and immune‑modulating activity reported in solid tumors and ARDS.
MiNK Therapeutics (NASDAQ: INKT) on November 20, 2025 published preclinical data for MiNK-215, an allogeneic, IL-15–enhanced FAP-targeting CAR-iNKT designed to remove FAP+ cancer-associated fibroblasts and boost immune infiltration in solid tumors.
Key preclinical findings show MiNK-215: dismantles stromal barriers, selectively eliminates FAP+ fibroblasts, remodels the tumor microenvironment, activates dendritic cell and antigen-presentation pathways, repolarizes macrophages to a pro-inflammatory state, and enables deep tumor-specific T cell infiltration in refractory lung and MSS colorectal cancer models.
MiNK-215 is described as an off-the-shelf therapy manufacturable at scale to address solid tumors resistant to checkpoint inhibitors.
MiNK Therapeutics (NASDAQ: INKT) reported Q3 2025 results and clinical progress on its allogeneic iNKT platform. Key clinical highlights include durable responses with agenT-797 in checkpoint- and chemotherapy-refractory solid tumors, including complete remissions >2 years and multi-year survivors, with no ≥Grade 3 CRS or neurotoxicity reported.
The company launched an NIH- and philanthropically funded GvHD collaboration with UW–Madison and plans a Phase 2+ severe pulmonary disease trial using FDA-validated endpoints. Leadership additions target pulmonary, trauma, and biodefense expertise. Cash was $14.3M at 9/30/25 (plus $1.2M subsequent raise), providing runway through 2026.
MiNK Therapeutics (NASDAQ: INKT) reported updated SITC 2025 results for allo-iNKT therapy agenT-797 in PD-1–refractory solid tumors showing durable survival and immune reactivation.
Key findings include a reported median overall survival of ~23 months, multiple tumor-specific OS signals (e.g., germ cell >33+ months, thymoma >39+ months, gastric >27 months, cholangiocarcinoma >21 months), complete remission >2 years in one metastatic germ-cell patient, evidence of tumor-immune remodeling, and a favorable safety profile with no DLTs or Grade ≥3 CRS/neurotoxicity.
MiNK Therapeutics (NASDAQ: INKT) will report third quarter 2025 financial results before the market opens on Friday, November 14, 2025.
The company will host a conference call and webcast at 8:30 a.m. ET the same day to discuss results, recent clinical progress and upcoming corporate milestones. MiNK recently presented late‑breaking data at the 2025 SITC Annual Meeting where its agenT-797 iNKT cell therapy showed durable immune reconstitution and signals of activity in patients with advanced solid tumors.
A live webcast and replay will be available from the company’s Events & Presentations page; dial‑in and webcast links are provided for investors.
MiNK Therapeutics (NASDAQ: INKT) will present late-breaking Phase 1 data for AgenT-797, an allogeneic iNKT cell therapy, at the 40th Annual Society for Immunotherapy of Cancer (SITC) meeting, November 7–9, 2025.
The poster (LBA #1344) titled “AgenT-797, an Allogeneic iNKT Cell Therapy, Demonstrates Durable Clinical Activity in Solid Tumors: Updated Phase 1 Findings” will report updated safety and efficacy results from the ongoing Phase 1 study in advanced solid tumors.
Presentation by Dr. Benjamin Garmezy will be in Prince George ABC Exhibit Halls, Gaylord National Resort & Convention Center, National Harbor, MD, on Saturday, November 8: poster attendance 12:15–1:45 PM ET and 5:10–6:35 PM ET.
MiNK Therapeutics (Nasdaq: INKT) has appointed Colonel (Ret.) John B. Holcomb, MD, FACS to its Board of Directors. Dr. Holcomb brings extensive expertise in trauma and critical care medicine, having served 23 years in the U.S. Army and authored over 780 peer-reviewed publications.
Dr. Holcomb joins alongside recently appointed pulmonary critical care expert Dr. Terese Hammond, strengthening MiNK's leadership as it develops invariant natural killer T (iNKT) cell therapies for immune-mediated diseases, pulmonary disorders, and global health security challenges. His expertise in trauma medicine, immune activation, and clinical trial execution will be valuable as MiNK advances its therapeutic programs into late-stage development.
MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in invariant natural killer T (iNKT) cell therapies, announced that CEO Dr. Jennifer Buell will deliver a plenary address at the 10th Annual CAR-TCR Summit in Boston, MA (September 23-26, 2025).
During her presentation, Dr. Buell will share first-in-human data from MiNK's iNKT platform, demonstrating durable disease reversal and steroid-free remission in severe immune collapse. The company's off-the-shelf approach is designed to be administered without HLA matching or lymphodepletion, focusing on treating autoimmunity and pulmonary failure.
MiNK Therapeutics (NASDAQ: INKT) has appointed Dr. Terese C. Hammond as Head of Inflammatory and Pulmonary Diseases. Dr. Hammond, a renowned expert in pulmonary and critical care medicine, has been the lead author of MiNK's Nature Communications publication on their iNKT cell therapy (agenT-797) in acute respiratory distress syndrome (ARDS).
In her new role, Dr. Hammond will lead two priority programs: an upcoming grant-funded clinical trial in graft-versus-host disease (GVHD) and a planned late-stage trial in severe pulmonary disease. Her previous clinical work has shown meaningful survival benefits and reduced infectious complications in severe acute lung injury and life-threatening hypoxemic pneumonia.
MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company, reported significant Q2 2025 milestones and financial results. The company achieved a notable breakthrough with a durable complete remission in metastatic testicular cancer using their agenT-797 therapy, published in Nature's Oncogene.
MiNK secured substantial funding through two non-dilutive grants from the Department of Defense for GvHD research and raised $13 million through equity sales post-Q2, extending their cash runway beyond mid-2026. The company reported a Q2 2025 net loss of $4.2 million ($1.06 per share) compared to $2.7 million in Q2 2024, with cash and equivalents of $1.6 million at quarter-end.
FAQ
What is the current stock price of Mink Therapeutics (INKT)?
What is the market cap of Mink Therapeutics (INKT)?
